Because extracellular HIV RNA increases to high levels soon after infection [12], the sensitivity of tests detecting HIV RNA may be adequate for early diagnosis of perinatal infection. We used diagnostic DNA-PCR to detect infant infection and
In the United States, nearly all new human immunodeficiency virus (HIV) infections in children are acquired through perinatal transmission. The accurate and timely detection of HIV in early infancy has become increasingly important because strategies for the medical management of children born to HIV-infected mothers [1] (prevention of opportunistic infections [2] , treatment strategies, and inclusion in clinical trials) rely on knowledge of HIV infection status. However, because maternal antibodies are passively transferred to the infant, HIV antibody testing cannot be used to diagnose infection until the second year of life [3] . Efforts to overcome this problem have included evaluation of new bands on serial Western blots [4] , monitoring of antibody titer to detect increases indicative of infant infection [5] , and evaluation of infant-specific (IgM and IgA) antibodies to HIV [4, 6] . Other efforts have focused on testing for virus (culture) [7] , viral antigen (p24) [8] , or proviral DNA using polymerase chain reaction (DNA-PCR) [9] . Culture and DNA-PCR testing are highly sensitive [7, 9] and specific [7, 10, 11] in infants by age 3-6 months and possibly earlier (1-2 months) [10] .
Because extracellular HIV RNA increases to high levels soon after infection [12] , the sensitivity of tests detecting HIV RNA may be adequate for early diagnosis of perinatal infection. We used diagnostic DNA-PCR to detect infant infection and evaluated plasma HIV RNA in samples obtained early in life from HIV-infected infants to determine relative sensitivities (compared with DNA-PCR) for detection of HIV infection. We also tested specimens from a small sample of perinatally exposed infants who seroreverted to look for early HIV RNA replication in children who were ultimately found to be uninfected.
Materials and Methods
Study population. Plasma viral RNA testing (see below) for early detection of HIV infection was analyzed among infants born to HIV-infected women who were enrolled from April 1990 to August 1994 in the New York City (NYC) Perinatal HIV Transmission Collaborative Study, a longitudinal study of perinatal HIV transmission and pediatric HIV-related disease progression at seven NYC health care institutions. Enrollment criteria and protocol design for this study have been described [13] . Women were enrolled before or within 2 weeks after giving birth. Both the HIV-infected women and their infants were examined at regular intervals. For the infants, a medical history, physical examination, and phlebotomy were done at birth and during scheduled followup visits.
Sample inclusion criteria. A previous study [14] identified all HIV-infected women in this NYC cohort whose infants were perinatally infected and who had available maternal plasma specimens near the time of delivery. For the current investigation, we identified all repository plasma samples obtained from these infants from birth to their first birthday. In addition, specimens obtained from 8 seroreverting infants (EIA-negative for HIV on a>2 occasions) born to HIV-infected mothers were examined by HIV RNA quantitation and DNA-PCR. Two of these seroreverting infants had a single positive or indeterminate DNA-PCR result in the first 3 months of life followed by consistently negative DNA-PCR results in subsequent specimens. For each infant, initial and subsequent specimens were HLA-concordant (i.e., there was no evidence of specimen mix-up). The other 6 infants were born to HIV-infected mothers who were considered at high risk for transmitting HIV to their infants because they had HIV RNA > 10,000 viral copies/mL plasma (median, 32,000) and had AIDS or HIV-associated symptoms and low CD4 T lymphocyte counts near the time of delivery (range, 29-252 cells/mL).
Sample collection. Heparinized blood samples from infants were collected and shipped at ambient temperature by overnight mail to the CDC for separation of plasma and peripheral blood mononuclear cells (PBMC) with ficoll-hypaque. The specimens were stored at -700C until DNA-PCR testing, typically within 1 week of specimen collection. Total time from phlebotomy to freezing was -24-30 h for each specimen. Plasma samples were stored frozen in a separate CDC facility.
Laboratory testing. Routine laboratory testing of infant blood samples included PCR of the earliest available infant PBMC specimens to detect the presence of HIV proviral DNA as previously described [1 ] . PBMC were processed, and DNA was extracted by the detergent-proteinase K procedure as described [9] . Diagnostic DNA PCR was done using two primer pairs (SK38/SK39 and SK145/SK150) at 96rC for 1 min, 55jC for 30 s, and 600C for 1.5 min for 35 cycles. Thermocycling was done in a PCR system (GeneAmp 9600; Perkin-Elmer Cetus, Branchburg, NJ) without an oil overlay. HIV DNA was detected using a chemiluminescent DNA probe and detection system (Accusearch; Gen-Probe, San Diego) with HIV-1 gag-I/gag-2 and gag-3/gag-4 probes.
Assay for plasma HIV RNA. Plasma HIV RNA was measured at the CDC using a recently developed isothermal nucleic acid amplification assay (NASBA HIV RNA QT kit; Organon-Teknika, Durham, NC) adapted for use with HIV [15] . The assay consists of three stages: isolation of nucleic acids from patient specimens and the addition of three internal RNA standards, then amplification of all RNAs with an enzyme solution containing avian myeloblastosis virus-reverse transcriptase, RNase H, and T-7 polymerase, followed by detection using the NASBA QR system electrochemiluminescence principle. The NASBA QT system calculates the amount of RNA in the original sample based on data generated from native RNA and the three synthetic internal RNA viral calibrators. The assay threshold of sensitivity is 100 HIV RNA copies per input volume or 1000 HIV RNA copies for this analysis. The assay was done blinded to all other test results according to the manufacturer's specifications.
To verify that plasma specimens with discordant HIV DNA-PCR results came from the same study subject, HLA DQ PCR amplification and typing using the AmpliType assay (Perkin-Elmer) were done on DNA from successive infant samples.
Statistical analysis. For analysis of test sensitivity, DNA-PCR-positive and "not positive" (negative and indeterminate) results were compared with HIV RNA results above (positive) and below (negative) the limit of detection for the test (1000 copies/ mL plasma). Logio transformations of RNA copy number were calculated because of the nonnormal distribution of virus load values. Test measures were compared and evaluated for differences in means (Student's t test) or proportions (binomial test). All probability values are two-tailed; the threshold of statistical significance was set at P = .05.
Results
From 49 HIV-infected infants, 108 same-draw samples of PBMC for DNA-PCR and plasma for quantitative HIV RNA testing were obtained (range, 1-4 samples/infant). Infant age at sampling ranged from birth to 318 days. Sixteen infants received antiretroviral therapy during their first year of life, but only 2 received an antiretroviral drug before plasma specimens were collected (described below); all specimens (n = 4) from the 2 infants were positive by both HIV RNA and DNA-PCR testing. 
